Ocrelizumab Extension Study in Multiple Sclerosis (OleroMAX)

Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoints: Change From Baseline to End of Study in the Physical Functioning Score of the Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function… at 5 years and Number of Eligible Participants who Have Received Access to Ocrelizumab in the Study at 5 years. Started Dec 2024; status: recruiting.